Sleeping Pills and Quality of Wake Time: The Missing Link

Sohil Khan1,2,3*, Treasure M McGuire1,2 and Helen S Heussler1,2

1 School of Pharmacy, Griffith University, Gold Coast, Australia
2 Mater Research Institute, Mater Health Services, South Brisbane, Australia
3 Mater Pharmacy Services, Mater Health Services, South Brisbane, Australia

Abstract

Background: The rising incidence of insomnia in a 24/7 global society quantifies the burden for the individual, in terms of reduced quality of life (QOL), and for society at large, in terms of work absenteeism, disability, and health care costs.

Aim: To evaluate research on hypnosedatives (benzodiazepines, non-benzodiazepines) and complementary medicines in paediatric insomnia where quality of wake time is one of the key efficacy outcomes.

Design and setting: Retrospective data analysis of clinical studies in paediatric insomnia

Methods: A systematic review of clinical studies of hypnosedatives and complementary medicines in paediatric insomnia was conducted. PubMed and Cochrane Central Register of Controlled Trials (January 2002-August 2013) were searched for studies in children aged 3 to 18 years (male or female). Quality of wake time and/or health related QOL parameters were assessed as the outcomes.

Results: From 31 potentially relevant studies, only one, involving melatonin, met the inclusion criteria. One hundred and forty six children (aged 3 to15 years 8 months) diagnosed with insomnia were evaluated in a 12 week double masked randomised placebo controlled phase III multi-centre trial. Child behaviour and family functioning showed some improvement and favoured use of melatonin but was not statistically significant. There were no controlled clinical studies evaluating the impact of benzodiazepines and non-benzodiazepines hypnosedatives on quality of wake time in the management of paediatric insomnia.

Conclusion: Data on quality of wake time in children with insomnia are scarce. Research has focused on addressing the metrics of sleep, with quality of wake time notably ignored. QOL measurement provides valuable information about the psychological and social impact of treatment on children with insomnia. Complementary medicines such as melatonin appear to improve the quality of wake time in paediatric insomnia where there are co-morbid conditions; but further research is needed.

Keywords: Insomnia; Benzodiazepines; Non-benzodiazepines; Melatonin; Sleep; Children; Quality of life

Introduction

Human beings spend approximately one-third of their lifetime sleeping [1]. As one of the most fundamental processes of life, sleep has attracted a great deal of attention from ancient philosophers to present day biomedical researchers. The rising incidence of insomnia in a 24/7 global society continues to create increasing demands that pose significant challenges to sleep research and circadian physiology.

A recently published epidemiological study [2] quantifies the burden of chronic insomnia for the individual, in terms of reduced Quality of Life (QOL), and for society at large, in terms of work absenteeism, disability and health care costs. The incidence is surprisingly high in the paediatric population, with a quarter of all children experiencing sleep problems. In children with visual impairment and neurodevelopmental disorders, the incidence is as high as 80% [3]. It is likely that this also has an impact on the carers of the affected child.

A sleep disorder exists when a lower quality of sleep results in impaired functioning or excessive sleepiness. For the past four decades, prescription hypnosedatives (benzodiazepine or non-benzodiazepine) have been widely used in the management of sleep disorders in adults and children. However, the risk associated with their chronic use (dependence, increased abuse potential, withdrawal symptoms) is alarming [4]. Recently, complementary medicines such as melatonin and valerian have gathered interest in sleep medicine. Prescriptions for sleep problems are common with melatonin, clonidine and antihistamines amongst the most frequent in paediatric practice [5]. There is significant variation in prescribing pharmacotherapeutic options in insomnia with lack of consensus based guidelines in diverse patient population. When novel hypnosedatives are developed, the focus tends to be on the statistically significant increase in total sleep time (marginal in minutes) during the night instead of the effects on the quality of wakefulness [1]. Pharmaceutical companies are focussed heavily on the metrics of sleep; and have neglected quality of wake time as a key measure of hypnosedatives efficacy, yet quality of wake time is a key measure of hypnosedatives efficacy, yet quality of wake time as a key measure of hypnosedatives efficacy, yet quality of wake time as a key measure of hypnosedatives efficacy, yet quality of wake time as a key measure of hypnosedatives efficacy.
time is an integral domain in the definition of insomnia disorders in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, described as “… causing clinically significant distress or impairment in social, occupational or other important areas of functioning” [6].

Poor sleep can exacerbate medical, psychiatric or developmental conditions; and insomnia has been a contributing factor in traffic and work-related accidents [2]. High risk patients, with underlying co-morbidities such as anxiety, depression and chronic pain, are more prone to impaired daytime function. However, there are few studies involving currently marketed hypnotic agents that evaluate the extent of improvement (if any) in daytime functioning or the consequences of disrupted sleep. This is not surprising, as the cohort of primary insomniacs selected for clinical trials tend to be without co-morbidities. This differs significantly from the ‘real world’ scenario where people with multiple co-morbidities are more likely to suffer from, and be adversely affected by insomnia. This review aims to evaluate research on hypnotic and complementary medicines (e.g. melatonin) in paediatric insomnia where quality of wake time is one of the key efficacy outcomes.

**Method**

This systematic literature review included clinical trials that evaluated quality of wake time in paediatric insomnia. Participants included were children aged 3 to 18 years (male or female) on hypnotic agents (benzodiazepines or non-benzodiazepines), or complementary medicine for the management of insomnia. Both typically developing children with no co-morbidities and those with existing co-morbidities were included. PubMed and the Cochrane Central Register of Controlled Trials (January 2002 to August 2013) were searched using the following Medical Subject Heading [MeSH] terms: ‘quality of life’ AND [exp ‘child’ AND ‘sleep initiation and maintenance disorders’. Studies were then filtered to retrieve any involving a pharmacotherapeutic intervention - benzodiazepine, non-benzodiazepine or complementary hypnotic agents. The following string of terms was used: ‘hypnotics and sedatives’ OR [exp ‘plants’ OR ‘homeopathy’ OR ‘naturopathy’ OR [exp ‘phytotherapy’ OR [exp ‘medicine, traditional’ OR ‘horticultural therapy’ OR ‘melatonin’ OR ‘drugs Chinese herbal OR ‘plant extracts’ OR ‘complementary’ (mp) OR ‘herb’ (mp)]. Only studies published in English language were included. An extended search (hand search) technique was applied to retrieve any relevant cross-references (Table 1).

**Results**

Of 31 potentially relevant studies reviewed, 26 were excluded as cohorts included adults or insomnia was not the primary diagnosis. The remaining five were selected for detailed evaluation. Four studies were excluded as they lacked a pharmacotherapeutic intervention, leaving one study for inclusion in this systematic review (Figure 1).

A recently published, randomised controlled trial [11] of the complementary medicine – melatonin was included for evaluation in the systematic review. This trial assessed the effectiveness and safety of melatonin in treating severe sleep problems in children with neurodevelopmental disorders. One hundred and forty-six children (aged 3 to 15 years and 8 months) were studied in a double masked randomised placebo controlled phase III multi-centre trial in 19 hospitals across England and Wales. Immediate release melatonin or matching placebo capsules were administered 45 minutes before the child’s bedtime for a 12 week period. All children started with a 0.5 mg capsule in a dose escalation design to 2 mg, 6 mg, and 12 mg depending on their response to treatment. Total sleep time comprised the primary outcome. Secondary outcomes included sleep onset latency, assessments of child behaviour, family functioning, and adverse events. Sleep was measured with diaries and actigraphy. Melatonin increased total sleep time by 22.4 minutes (95% confidence interval 0.5 to 44.3 minutes) measured by sleep diaries (n=110) and 13.3 (−15.5 to 42.2) measured by actigraphy (n=59).

Quality of wake time was evaluated as a secondary outcome. Child behaviour and family functioning showed some improvement and favoured use of melatonin. Four questionnaires were administered: the Composite Sleep Disturbance Index (CSDI), Aberrant Behaviour Checklist (ABC) to assess behavioural problems, the family impact module of the Paediatric Quality of Life inventory (PedsQL) to assess the quality of life of the care giver; and the Epworth Sleepiness Scale (ESS) to assess the daytime sleepiness of the care giver. The ESS scale showed a clinically small but statistically significant improvement of 1.6 points on the 24 point scale for melatonin compared with placebo. The results of the PedsQL and ABC tended to favour melatonin but were not statistically significant.

A summary of the commonly used tools to evaluate QOL in

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Age (yrs) Mean</th>
<th>Objective</th>
<th>Study design</th>
<th>Medical co-morbidity</th>
<th>Type of sleep disorder</th>
<th>HRQOL tool</th>
<th>Study outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>de Serres et al.</td>
<td>101</td>
<td>6.2</td>
<td>Impact of adenotonsillectomy on HRQOL in children with OSDs</td>
<td>Prospective observational</td>
<td>OSD</td>
<td>OSD with restless sleep</td>
<td>Obstructive Sleep Disorders-6 survey (OSD-6)</td>
<td>Sleep disorder – an important domain that directly affects QOL</td>
</tr>
<tr>
<td>Rosen et al. [2002]</td>
<td>298</td>
<td>11.1</td>
<td>Extent of SDB with impairment of HRQOL</td>
<td>Longitudinal genetic-epidemiologic cohort study</td>
<td>Obesity, Asthma</td>
<td>SDB</td>
<td>Child Health Questionnaire (CHQ-PF50)</td>
<td>Decrements in HRQOL were measurable even with mild SDB; Increasing effects with more severe SDB</td>
</tr>
<tr>
<td>Hart et al. [2005]</td>
<td>80</td>
<td>11.2</td>
<td>Assess relationship between sleep disturbance and HRQOL</td>
<td>Retrospective review of a clinical database</td>
<td>Obesity, pulmonary and neurologic disorders</td>
<td>Behaviour and biological origin</td>
<td>Child Health Questionnaire (CHQ-PF50)</td>
<td>Variety of HRQOL decrements experienced that may benefit from intervention</td>
</tr>
<tr>
<td>Diez-Montiel et al.</td>
<td>101</td>
<td>4.1</td>
<td>Long term impact of tonsillectomy/adenoidectomy in children with OSA</td>
<td>Prospective controlled study</td>
<td>SDB, OSA</td>
<td>SDB, OSA</td>
<td>OSDs-6 survey</td>
<td>Long term improvement in HRQOL after surgery in children with OSA</td>
</tr>
</tbody>
</table>

Key: OSD: Obstructive Sleep Disorders, SDB: Sleep disordered breathing ; OSA: Obstructive sleep apnoea

**Table 1**: Characteristics of excluded studies (after detailed evaluation).
Insomnia and other sleep problems in children are presented in Table 2. It should be noted that administration of such tools in children less than 5 years needed to be completed by their parents/care givers.

### Discussion

In recent times, measurement of QOL has added a new dimension to clinical trials and the drug development process. Results of epidemiological studies have demonstrated the increasing burden of chronic disease and its social impact, based on disability and not mortality. QOL measurement provides valuable information about the psychological and social impact of treatment on children, especially where differences in survival rates are anticipated. Despite the lack of a pharmacotherapeutic intervention in the four studies excluded from this systematic review, they serve to highlight the adverse impact of paediatric sleep disorders on HRQOL.

To the best of our knowledge, there is only one controlled trial that has evaluated the impact of a pharmacotherapeutic intervention on quality of wake time in paediatric insomnia. This study assessed the impact of melatonin on QOL and daytime functioning in children with neurodevelopmental disorders suffering from severe sleep problems [11]. Findings from measures of child behaviour and family QOL tended to favour melatonin but were not statistically significant. The authors justify this as the outcome measures were not sensitive enough over the study time period (12 weeks). The lack of studies addressing this issue with benzodiazepine or non-benzodiazepine hypnotic agents is surprising, considering their extensive use. Nonetheless, the melatonin study provides a baseline for future trials to focus on this neglected but an important parameter in sleep medicine – the quality of wake time.

A similar search in adult insomniacs with co-morbid conditions also retrieved only one placebo-controlled trial [18]. Claimed to be the first of its kind, the study demonstrated that long-term nightly treatment of primary insomnia with eszopiclone was able to enhance QOL, reduce work limitations, and reduce global insomnia severity, in addition to improving patient-reported sleep variables. Patient-reported sleep and daytime function were improved more with the hypnotic than with placebo at months 1-6 (duration: 6 months) (P<0.001). Furthermore, statistically significant improvements were observed with eszopiclone compared with placebo for the SF-36 domains of Physical Functioning, Vitality, and Social Functioning (P<0.05), and all domains of the work limitations questionnaire (P<0.05). As this trial was conducted in primary insomniacs, impact of quality of wake time from the findings may not be extrapolated to patients with co-morbid conditions.

The use of medication to manage insomnia often follows a ‘one-size-fits-all’ approach. Yet the nature of the sleep problem experienced by those with insomnia varies. At present, daytime performance is considered as an absence of impairment — improvement of function with benzodiazepines or benzodiazepine receptor agonists has never been demonstrated. There are a number of barriers in evaluating quality of wake time. One is the lack of subjective and objective parameters to evaluate the clinical effect. Validated tools designed to assess HRQOL (Table 2) would be suitable for evaluating daytime performance and QOL in paediatric sleep pharmacotherapy.

Insomniacs with co-morbid conditions (e.g. neurodevelopmental disorders or circadian rhythm sleep disorders) are presented with challenging therapeutic decisions. A recently published therapeutic guideline [19] highlighted the need for studies to identify how to optimally manage insomnia in patients with co-morbid conditions. Newer strategies such as chronobiotic therapies are under trial. Melatonin seems one of the promising options to address this unexplored yet an important clinical domain of sleep medicine.

### Implications for practice and research

- Despite their long history in the management of sleep disorders, there are no controlled clinical studies evaluating the impact of benzodiazepines and non-benzodiazepine hypnotic agents on quality of wake time in the management of paediatric insomnia.
- Complementary medicines such as melatonin appear to improve the quality of wake time in paediatric insomnia where there are co-morbid conditions (e.g. neurodevelopmental disorders, visual impairment and circadian rhythm sleep disorders). Further long term studies (more than 6 months) are needed.
There are number of good quality validated tools (outcome measures) to study the quality of wake time for therapeutic trials in insomnia although some of these may not be suitable where children are affected by disability.

### References


### Table 2: Summary of generic measures of health-related QOL used in paediatric sleep disorders.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Age range (years)</th>
<th>Concept</th>
<th>Child (self) Report</th>
<th>Parent (proxy) Report</th>
<th>Domain</th>
<th>Time to complete (min)</th>
<th>Reliability data</th>
<th>Validity data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Child Health and Illness Profile [12]</td>
<td>6-11 and 12-17</td>
<td>Measure based on a broad concept that includes evaluation of perception of well being and illness, participation in developmentally appropriate tasks, and activities or behaviours that promote or threaten health</td>
<td>X</td>
<td>X</td>
<td>Domain; Child edition (6-11 years); Adolescent edition (12-17 years)</td>
<td>30</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Child Health Questionnaire [13]</td>
<td>5-18</td>
<td>Measures health with regard to physical, psychological and social domains</td>
<td>X</td>
<td>X</td>
<td>11 domains; Self and Parent version</td>
<td>20</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Dartmouth Coop Functional Health Assessment Charts [14]</td>
<td>15 (median)</td>
<td>Measures exclusive dimensions of health and social problems through picture/word charts</td>
<td>X</td>
<td>6 charts (pictures and words)</td>
<td>15-20</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KINDL [15]</td>
<td>4-16</td>
<td>Describes physical, psychological, social, and functional aspects of well-being and functioning from patient’s perspective</td>
<td>X</td>
<td>X</td>
<td>6 domains</td>
<td>10</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Pediatric Quality of Life Questionnaire [16]</td>
<td>2-18</td>
<td>Evaluates physical, mental and social health of children and adolescents</td>
<td>X</td>
<td>X</td>
<td>4 domain, 23 items</td>
<td>5-10</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Quality of Life Profile – Adolescent Version [16]</td>
<td>14-20</td>
<td>Evaluates physical, psychological and spiritual parameters through being, belonging and becoming options</td>
<td>X</td>
<td>3 domains, 54 items</td>
<td>40</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warwick Child Health and Morbidity Profile [17]</td>
<td>0-5</td>
<td>Evaluates general, acute, chronic and functional health status and QOL</td>
<td>X</td>
<td>X</td>
<td>10 domains</td>
<td>10</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

**Inclusion of quality of wake time as a secondary outcome in pharmacotherapeutic studies will be a key step in addressing this neglected but significant aspect of sleep medicine.**